Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A, Bhatt N, Prakash SS, Biswas G, Nagarkar R, Roy B, Samal P, Agrawal N, Meshram S, Kaushal A, Satheesh CT, Wategaonkar R, Thiagarajan KV, Jain K, Vijayaveeran P, Mukherjee K, Singh K, Patil T, Jain A, Dolai TK, Jain M, Hingmire S, Gupta TC, Lakshmaiah KC, Rajamanickam D, Nemade B, Goyal V, Mahato P, Mendiratta SK, Doshi M. Patel A, et al. Among authors: nagarkar r. Cancer Chemother Pharmacol. 2023 Jun;91(6):457-468. doi: 10.1007/s00280-023-04530-x. Epub 2023 Apr 24. Cancer Chemother Pharmacol. 2023. PMID: 37093266 Free PMC article. Clinical Trial.
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.
Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S, Parmar D; Study Investigator Group. Chiradoni Thungappa S, et al. Among authors: nagarkar r. Clin Breast Cancer. 2022 Jun;22(4):300-307. doi: 10.1016/j.clbc.2021.11.006. Epub 2021 Nov 27. Clin Breast Cancer. 2022. PMID: 34955432 Clinical Trial.
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Stroyakovskiy DL, Fadeeva NV, Matrosova MP, Shelepen KG, Adamchuk GA, Roy B, Nagarkar R, Kalloli M, Zhuravleva D, Voevodin GD, Shustova MS, Kryukov F. Stroyakovskiy DL, et al. Among authors: nagarkar r. BMC Cancer. 2022 Feb 1;22(1):129. doi: 10.1186/s12885-022-09243-7. BMC Cancer. 2022. PMID: 35105329 Free PMC article. Clinical Trial.
Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer.
S PS, Nagarkar RV, Puligundla KC, N LK, Boya RR, Patel AB, Goyal L, Thoke A, Patel JG, Mehta AO, Patel GN, Khan MA, Ahmad I. S PS, et al. Eur J Pharm Sci. 2022 Sep 1;176:106248. doi: 10.1016/j.ejps.2022.106248. Epub 2022 Jun 28. Eur J Pharm Sci. 2022. PMID: 35777616 Free article. Clinical Trial.
Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients - a multicenter, randomized, comparative, phase II/III clinical study.
Satheesh CT, Taran R, Singh JK, Shrivastav SP, Vithalani NK, Mukherjee KK, Nagarkar RV, Maksud T, Mehta AO, Srinivasan K, Vikranth M, Sonawane SR, Ahmad A, Sheikh S, Ali SM, Patel R, Paithankar M, Patel L, Rajani A, Bunger D, Chaturvedi A, Ahmad I. Satheesh CT, et al. Among authors: nagarkar rv. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241236442. doi: 10.1177/17588359241236442. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38680290 Free PMC article.
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
Buske C, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Kwak L, Kim WS, Lee S, Kim S, Ahn K, Ogura M. Buske C, et al. Among authors: nagarkar r. Blood Adv. 2021 Sep 14;5(17):3354-3361. doi: 10.1182/bloodadvances.2021004484. Blood Adv. 2021. PMID: 34477816 Free PMC article. Clinical Trial.
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, Supe P, Godara I, Revanna R, Nagarkar R, Sanmukhani J, Dey A, Rajanathan TMC, Kansagra K, Koradia P; ZyCoV-D phase 3 Study Investigator Group. Khobragade A, et al. Among authors: nagarkar r. Lancet. 2022 Apr 2;399(10332):1313-1321. doi: 10.1016/S0140-6736(22)00151-9. Lancet. 2022. PMID: 35367003 Free PMC article. Clinical Trial.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
64 results